1
|
Zhou H, Li M, Liu H, Liu Z, Wang X, Wang S. Design, synthesis, and biological evaluation of piperazine derivatives involved in the 5-HT 1AR/BDNF/PKA pathway. J Enzyme Inhib Med Chem 2024; 39:2286183. [PMID: 38078358 DOI: 10.1080/14756366.2023.2286183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2023] [Accepted: 11/16/2023] [Indexed: 12/18/2023] Open
Abstract
In this study, four series of piperazine derivatives were designed, synthesised and subjected to biological test, and compound 6a with potential antidepressant activity was obtained. An affinity assay of compound 6a with 5-hydroxytryptamine (serotonin, 5-HT)1A receptor (5-HT1AR) was undertaken, and the effects on the 5-HT level in the brains of mice were also tested. The results showed that compound 6a had the best affinity with 5-HT1AR (Ki = 1.28 nM) and significantly increased the 5-HT level. The expression levels of 5-HT1AR, BDNF, and PKA in the hippocampus were analysed by western blot and immunohistochemistry analyses. The results showed that the expression of 5-HT1AR, BDNF, and PKA in the model group was reduced compared to that of the control group, and compound 6a could reverse this phenomenon. Molecular docking was performed to investigate the interactions of the studied compound 6a with 5-HT1AR on the molecular level.
Collapse
Affiliation(s)
- Hao Zhou
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, Shandong, China
| | - Mengjiao Li
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, Shandong, China
| | - Hui Liu
- College of Pharmacy, Yanbian University, Yanji, Jilin, China
| | - Zheng Liu
- School of Medicine, Foshan University, Foshan, Guangdong, China
| | - Xuekun Wang
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, Shandong, China
| | - Shiben Wang
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, Shandong, China
| |
Collapse
|
2
|
Han Z, Li J, Xu Z, Su Y, Wang Y, Zhuo L, Du J, Zhu C, Hao X. Design and synthesis of novel quinazolin-4(1H)-one derivatives as potent and selective inhibitors targeting AKR1B1. Arch Pharm (Weinheim) 2023; 356:e2200577. [PMID: 36707406 DOI: 10.1002/ardp.202200577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 12/09/2022] [Accepted: 12/30/2022] [Indexed: 01/29/2023]
Abstract
Inhibition of aldose reductase (AKR1B1) is a promising option for the treatment of diabetic complications. However, most of the developed small molecule inhibitors lack selectivity or suffer from low bioactivity. To address this limitation, a novel series of quinazolin-4(1H)-one derivatives as potent and selective inhibitors of AKR1B1 were designed and synthesized. Aldose reductase inhibitory activities of the novel compounds were characterized by IC50 values ranging from 0.015 to 31.497 μM. Markedly enhanced selectivity of these derivatives was also recorded, which was further supported by docking studies. Of these inhibitors, compound 5g exhibited the highest inhibition activity with selectivity indices reaching 1190.8. The structure-activity relationship highlighted the importance of N1-acetic acid and N3-benzyl groups with electron-withdrawing substituents on the quinazolin-4(1H)-one scaffold for the construction of efficient and selective AKR1B1 inhibitors.
Collapse
Affiliation(s)
- Zhongfei Han
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Jiahui Li
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Zilu Xu
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Yu Su
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Yihan Wang
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Lili Zhuo
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Jiaming Du
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Changjin Zhu
- Department of Applied Chemistry, Beijing Institute of Technology, Beijing, China
| | - Xin Hao
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| |
Collapse
|
3
|
Tassopoulou VP, Tzara A, Kourounakis AP. Design of Improved Antidiabetic Drugs: A Journey from Single to Multitarget Agents. ChemMedChem 2022; 17:e202200320. [PMID: 36184571 DOI: 10.1002/cmdc.202200320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 09/27/2022] [Indexed: 01/14/2023]
Abstract
Multifactorial diseases exhibit a complex pathophysiology with several factors contributing to their pathogenesis and development. Examples of such disorders are neurodegenerative (e. g. Alzheimer's, Parkinson's) and cardiovascular diseases (e. g. atherosclerosis, metabolic syndrome, diabetes II). Traditional therapeutic approaches with single-target drugs have been proven, in many cases, unsatisfactory for the treatment of multifactorial diseases such as diabetes II. The well-established by now strategy of multitarget drugs is constantly gaining interest and momentum, as a more effective approach. The development of pharmacomolecules able to simultaneously modulate multiple relevant-to-the-disease targets has already several successful examples in various fields and has, as such, inspired the design of multitarget antidiabetic agents; this review highlights the design aspect and efficacy of this approach for improved antidiabetics by presenting several examples of successful pharmacophore combinations in (multitarget) agents that modulate two or more molecular targets involved in diabetes II, resulting in a superior antihyperglycemic profile.
Collapse
Affiliation(s)
- Vassiliki-Panagiota Tassopoulou
- Department of Medicinal Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, 15771, Athens, Greece
| | - Ariadni Tzara
- Department of Medicinal Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, 15771, Athens, Greece
| | - Angeliki P Kourounakis
- Department of Medicinal Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, 15771, Athens, Greece
| |
Collapse
|
4
|
Tanawattanasuntorn T, Rattanaburee T, Thongpanchang T, Graidist P. Trans-(±)-Kusunokinin Binding to AKR1B1 Inhibits Oxidative Stress and Proteins Involved in Migration in Aggressive Breast Cancer. Antioxidants (Basel) 2022; 11:antiox11122347. [PMID: 36552555 PMCID: PMC9774946 DOI: 10.3390/antiox11122347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Revised: 11/12/2022] [Accepted: 11/19/2022] [Indexed: 11/29/2022] Open
Abstract
Synthetic trans-(±)-kusunokinin ((±)KU), a potential anticancer substance, was revealed to have an inhibitory effect on breast cancer. According to the computational modeling prediction, AKR1B1, an oxidative stress and cancer migration protein, could be a target protein of trans-(-)-kusunokinin. In this study, we determined the binding of (±)KU and AKR1B1 on triple-negative breast and non-serous ovarian cancers. We found that (±)KU exhibited a cytotoxic effect that was significantly stronger than zopolrestat (ZP) and epalrestat (EP) (known AKR1B1 inhibitors) on breast and ovarian cancer cells. (±)KU inhibited aldose reductase activity that was stronger than trans-(-)-arctiin ((-)AR) but weaker than ZP and EP. Interestingly, (±)KU stabilized AKR1B1 on SKOV3 and Hs578T cells after being heated at 60 and 75 °C, respectively. (±)KU decreased malondialdehyde (MDA), an oxidative stress marker, on Hs578T cells in a dose-dependent manner and the suppression was stronger than EP. Furthermore, (±)KU downregulated AKR1B1 and its downstream proteins, including PKC-δ, NF-κB, AKT, Nrf2, COX2, Twist2 and N-cadherin and up-regulated E-cadherin. (±)KU showed an inhibitory effect on AKR1B1 and its downstream proteins, similar to siRNA-AKR1B1. Interestingly, the combination of siRNA-AKR1B1 with EP or (±)KU showed a greater effect on the suppression of AKR1B1, N-cadherin, E-cadherin and NF-κB than single treatments. Taken together, we concluded that (±)KU-bound AKR1B1 leads to the attenuation of cellular oxidative stress, as well as the aggressiveness of breast cancer cell migration.
Collapse
Affiliation(s)
- Tanotnon Tanawattanasuntorn
- Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
| | - Thidarath Rattanaburee
- Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
| | - Tienthong Thongpanchang
- Department of Chemistry and Center of Excellence for Innovation in Chemistry (PERCH-CIC), Faculty of Science, Mahidol University, Bangkok 10400, Thailand
| | - Potchanapond Graidist
- Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
- Correspondence: ; Tel.: +66-74-45-1184
| |
Collapse
|
5
|
Bailly C. Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer. Eur J Pharmacol 2022; 931:175191. [PMID: 35964660 DOI: 10.1016/j.ejphar.2022.175191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 07/18/2022] [Accepted: 08/05/2022] [Indexed: 11/19/2022]
Abstract
Epalrestat (EPA) is a potent inhibitor of aldose reductases AKR1B1 and AKR1B10, used for decades in Japan for the treatment of diabetic peripheral neuropathy. This orally-active, brain-permeable small molecule, with a relatively rare and essential 2-thioxo-4-thiazolidinone motif, functions as a regulator intracellular carbonyl species. The repurposing of EPA for the treatment of pediatric rare diseases, brain disorders and cancer has been proposed. A detailed analysis of the mechanism of action, and the benefit of EPA to combat advanced malignancies is offered here. EPA has revealed marked anticancer activities, alone and in combination with cytotoxic chemotherapy and targeted therapeutics, in experimental models of liver, colon, and breast cancers. Through inhibition of AKR1B1 and/or AKR1B10 and blockade of the epithelial-mesenchymal transition, EPA largely enhances the sensitivity of cancer cells to drugs like doxorubicin and sorafenib. EPA has revealed a major anticancer effect in an experimental model of basal-like breast cancer and clinical trials have been developed in patients with triple-negative breast cancer. The repurposing of the drug to treat chemo-resistant solid tumors seems promising, but more studies are needed to define the best trajectory for the positioning of EPA in oncology.
Collapse
Affiliation(s)
- Christian Bailly
- OncoWitan, Scientific Consulting Office, Lille, Wasquehal, 59290, France.
| |
Collapse
|
6
|
Zhu J, Qi G, Kuang Y, Zhao Y, Sun X, Zhu C, Hao X, Han Z. Identification of 9H-purin-6-amine derivatives as novel aldose reductase inhibitors for the treatment of diabetic complications. Arch Pharm (Weinheim) 2022; 355:e2200043. [PMID: 35466439 DOI: 10.1002/ardp.202200043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 03/29/2022] [Accepted: 03/31/2022] [Indexed: 11/09/2022]
Abstract
A series of 9H-purin-6-amine derivatives as aldose reductase (ALR) inhibitors were designed and synthesized. Most of these derivatives, having a C6-substituted benzylamine side chain and N9 carboxylic acid on the core structure, were found to be potent and selective ALR inhibitors, with submicromolar IC50 values against ALR2. Particularly, compound 4e was the most active with an IC50 value of 0.038 μM, and it was also proved to be endowed with excellent inhibitory selectivity. The structure-activity relationship and molecular docking studies highlighted the importance of the carboxylic acid head group along with different halogen substituents on the C6 benzylamine side chain of the 9H-purin-6-amine scaffold for the construction of strong and selective ALR inhibitors.
Collapse
Affiliation(s)
- Junkai Zhu
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Gang Qi
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Yan Kuang
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Yating Zhao
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Xinjie Sun
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Changjin Zhu
- Department of Applied Chemistry, Beijing Institute of Technology, Beijing, China
| | - Xin Hao
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
| | - Zhongfei Han
- Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China.,Department of Applied Chemistry, Beijing Institute of Technology, Beijing, China
| |
Collapse
|